NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/02/2022
Back to search
Official data from USPTO
HELIUS THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
HELIUS THERAPEUTICS
ST13
US500000079285864Class
1, 5, 35, 44
Filing
79285864
Registration
6578319
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
47
Latest update
12/02/2022
Trademark type
Word
Nice classes
1, 5, 35, 44
Filing date
12/18/2019
Registration date
12/07/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/07/2021
Last transaction
12/07/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
NZ
Examiner
STRUCK, ROBERT J
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
HELIUS THERAPEUTICS LIMITED
HELIUS THERAPEUTICS LIMITED
Representatives
Sarah P. Harrell BARNES & THORNBURG LLP
Technical classification
Nice Classes
Class 1Class 5Class 35Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Active chemical ingredients for use in the manufacture of pharmaceuticals solely derived from cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis and not containing CBD
Class 5
Pharmaceutical preparations for the treatment of painappetite lossepilepsy and seizuresglaucomasleep disordersmuscle spasmsnauseagastrointestinal disorderscancerAlzheimer's diseasesymptoms of post-traumatic stress disorderanxietydepressionschizophreniaaddiction disorderinflammationmultiple sclerosispre-menstrual syndrome; medicinal preparations for the treatment of painappetite lossepilepsy and seizuresglaucomasleep disordersmuscle spasmsnauseagastrointestinal disorderscancerAlzheimer's diseasesymptoms of post-traumatic stress disorderanxietydepressionschizophreniaaddiction disorderinflammationmultiple sclerosispre-menstrual syndrome; herbal preparations and extracts for medicinal use; medical cannabis and derivatives thereof namelymedicinal herbs and medicinal herb extracts; herbal supplements; all of the foregoing containing or solely derived from cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis and not containing CBD
Class 35
Retail and wholesale store services featuring cannabis medicinal herbscannabis oil and derivatives thereof all of the foregoing containing or solely derived from cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis and not containing CBD; retail and wholesale store services featuring hemp and cannabis cosmetic products and accessoriesfood productsbeveragespersonal care preparationsskin care preparationsall of the foregoing containing or solely derived from cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis and not containing CBD; providing consumer information featuring the ratingsreviews and recommendations on marijuana and medical marijuana products via a website
Class 44
Cultivation of plants for others featuring solely cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; consultancy services relating to the cultivation of plants; cultivation and breeding for others of cannabis all of the foregoing containing or solely derived from cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; providing health and agricultural information in the field of medical marijuana and cannabis via a website; providing medical information featuring indications and effects of particular cannabis strainsthe benefits of medical marijuanamarijuanacannabis and research related to cannabis and marijuana via a website
Publications
History of USPTO decisions and trademark events.
47 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/05/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/23/2022
FIMP
FINAL DISPOSITION PROCESSED
05/23/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/07/2022
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
01/08/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/18/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
12/07/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
11/14/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/27/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
10/27/2021
GPNX
NOTIFICATION PROCESSED BY IB
10/04/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/21/2021
PUBO
PUBLISHED FOR OPPOSITION
09/21/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/01/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/01/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/01/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/19/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
08/16/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/12/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
08/12/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/12/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
07/15/2021
ALIE
ASSIGNED TO LIE
07/15/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/15/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
07/15/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/15/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/04/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/04/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
06/04/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/29/2021
GNFR
FINAL REFUSAL E-MAILED
04/29/2021
CNFR
FINAL REFUSAL WRITTEN
04/29/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/30/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/30/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/30/2021
RFNT
REFUSAL PROCESSED BY IB
10/18/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/30/2020
RFRR
REFUSAL PROCESSED BY MPU
09/30/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/10/2020
CNRT
NON-FINAL ACTION WRITTEN
09/09/2020
DOCK
ASSIGNED TO EXAMINER
09/09/2020
MAFR
APPLICATION FILING RECEIPT MAILED
06/02/2020
DOCK
ASSIGNED TO EXAMINER
05/28/2020
DOCK
ASSIGNED TO EXAMINER
05/27/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/27/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/21/2020
Continuous trademark protection
Get notified about every new filing that threatens HELIUS THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.